Resumed Outperform X

BCEL Atreca

Robert W. Baird

$30 $27

Initiated Buy X

BCEL Atreca

Jefferies

$30

Initiated Buy X

BCEL Atreca

Canaccord Genuity

$23

Initiated Outperform X

BCEL Atreca

Cowen

Initiated Outperform X

BCEL Atreca

Evercore ISI

Initiated Buy X

BCEL Atreca

Stifel

$28

BCEL  Atreca, Inc.

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.